From Startup Sophiris Bio
SAN DIEGO and VANCOUVER, British Columbia, Aug. 29, 2018 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:50 a.m. EDT in New York, NY.
The discussion will be webcast live and can be accessed through the Investor Relations page at www.sophirisbio.com. A replay of the presentation will be available on the Company’s website for 90 days.
About Sophiris Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells. For more information, please visit www.sophirisbio.com.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:Peter SloverChief Financial Officer(858) 777-1760
Corporate Communications and Media Contact:Jason SparkCanale Communications(619) firstname.lastname@example.org
Investor Contact:Bill Slattery, Jr.Burns McClellan(212) email@example.com
View original content with multimedia:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-the-hc-wainwright-20th-annual-global-investment-conference-300704374.html
SOURCE Sophiris Bio Inc.
Please visit their site for more information: Sophiris Bio.com
All,Biotechnology,Healthcare News,Startup News